Equities analysts predict that Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) will announce earnings of ($0.06) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Eyegate Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.06). Eyegate Pharmaceuticals posted earnings per share of ($0.07) in the same quarter last year, which indicates a positive year over year growth rate of 14.3%. The company is scheduled to announce its next quarterly earnings results on Friday, August 2nd.

On average, analysts expect that Eyegate Pharmaceuticals will report full-year earnings of ($0.21) per share for the current fiscal year, with EPS estimates ranging from ($0.23) to ($0.19). For the next fiscal year, analysts forecast that the company will post earnings of ($0.23) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Eyegate Pharmaceuticals.

EYEG traded down $0.04 on Thursday, reaching $0.25. The company had a trading volume of 1,374,326 shares, compared to its average volume of 545,375. Eyegate Pharmaceuticals has a 52-week low of $0.21 and a 52-week high of $0.86.

In other Eyegate Pharmaceuticals news, major shareholder Armistice Capital Master Fund purchased 549,647 shares of the firm’s stock in a transaction on Friday, March 29th. The shares were purchased at an average cost of $0.32 per share, with a total value of $175,887.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 43.90% of the company’s stock.

An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Acadian Asset Management LLC grew its holdings in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 28.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 97,723 shares of the specialty pharmaceutical company’s stock after purchasing an additional 21,700 shares during the quarter. Acadian Asset Management LLC owned approximately 0.22% of Eyegate Pharmaceuticals worth $46,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 40.10% of the company’s stock.

About Eyegate Pharmaceuticals

EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.

Further Reading: What is a Buy-Side Analyst?

Get a free copy of the Zacks research report on Eyegate Pharmaceuticals (EYEG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.